Associated Papers
Genetic landscape and therapeutic evolution of cyclophosphamide: spotlight on breast cancer.
Cao J et al.
Journal of Chemotherapy (florence, Italy), 2025
Genetic polymorphisms of ABCC2 and CBR3 can influence the efficacy and toxicity of doxorubicin therapy in Egyptian patients with non-Hodgkin lymphoma.
Elmekawy HA et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2025
Pharmacogenetic Analysis of an 8-Year Old Girl with Reye Syndrome Associated with Use of Naproxen.
Kim B et al.
The American Journal of Case Reports, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE et al.
Pharmacogenetics and Genomics, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor.
Ravegnini G et al.
The Pharmacogenomics Journal, 2019
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
Whole exome sequencing in three families segregating a pediatric case of sarcoidosis.
Calender A et al.
Bmc Medical Genomics, 2018
Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
Meißner T et al.
Cold Spring Harbor Molecular Case Studies, 2017
Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
Magdy T et al.
Pharmacology & Therapeutics, 2016
The chronological sequence of somatic mutations in early gastric carcinogenesis inferred from multiregion sequencing of gastric adenomas.
Lim CH et al.
Oncotarget, 2016
Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.
Cocca M et al.
Journal of Translational Medicine, 2016
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.
Simeon V et al.
International Journal of Molecular Sciences, 2015
Genetic factors affecting drug disposition in Asian cancer patients.
Syn NL et al.
Expert Opinion on Drug Metabolism & Toxicology, 2015
Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.
Voon PJ et al.
British Journal of Clinical Pharmacology, 2013
Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.
Windsor RE et al.
Cancer, 2012
Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.
Vianna-Jorge R et al.
Frontiers in Genetics, 2012
Pharmacogenetics of genes across the doxorubicin pathway.
Jamieson D et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS et al.
The Journal of Pharmacology and Experimental Therapeutics, 2010
Breast cancer in the personal genomics era.
Ellsworth RE et al.
Current Genomics, 2010
Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism.
Bains OS et al.
The Journal of Pharmacology and Experimental Therapeutics, 2010
Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression.
Zhang J et al.
Pharmaceutical Research, 2009
Pharmacogenetics in breast cancer therapy.
Tan SH et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2008
CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.
Lal S et al.
Cancer Science, 2008
Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.
Fan L et al.
Pharmacogenetics and Genomics, 2008